Show notes
This week, I spoke with Natalie Nairn, co-founder and CEO of Cyclera Therapeutics. Natalie is also a Termeer Fellow, and listeners of this podcast know how much I love the Termeer Foundation. We discuss her transition from chemical engineering to biomedical applications. She describes her unexpected path into the fun and volatile startup space, which led to her founding Cyclera. Natalie explains the importance of focusing in biotech development, the promising applications of Cyclera's technology in CNS therapeutics, and the challenges and opportunities in the current funding landscape. She also highlights the value of the Termeer fellowship in her career, the contrast between Boston and Seattle's biotech scenes, and the essential aspects of leadership and team cohesion. Finally, Natalie discusses her future goals for Cyclera and offers valuable advice for aspiring biotech founders.Get Natalie's recommended book! The Book of Delights: EssaysCYpHER: catalytic extracellular targeted protein degradation with high potency and durable effect | Nature CommunicationsConnect with Natalie on LinkedIn!Learn more about Cyclera TherapeuticsConnect with us!Link In with CarinaSubscribe here:AppleSpotifyGoogle PodcastRSS feedLearn more about Recruitomics ConsultingCheck out our reading listDownload our free startup resources guide to grow your biotech efficientlyIf you're on the job market, visit the Collaboratory Career Hub 00:00 Introduction and Early Aspirations00:33 Journey into Biomedical Engineering01:19 First Startup Experience03:40 Founding Cyclera05:02 Focus on CNS Therapeutics13:35 Challenges and Strategies in Biotech15:39 The Termeer Foundation Fellowship21:26 Biotech Networks: Boston vs. Seattle26:50 Future of Cyclera and Personalized Medicine32:45 Conclusion and Final Thoughts
